化疗联合贝伐单抗治疗非小细胞肺癌的临床研究

Clinical Study of Chemotherapy Combined With Bevacizumab in Treatment of Non-small Cell Lung Cancer

目的：探讨化疗联合贝伐单抗治疗非小细胞肺癌的临床研究。方法选取2013年11月～2014年11月我院接诊的44例非小细胞肺癌患者，按照入院的先后顺序分为实验组和对照组，实验组采用化疗联合贝伐单抗，对照组采用单纯化疗，观察两组患者的治疗效果。结果实验组患者的治疗总有效率明显高于对照组，差异显著，有统计学意义（P＆lt;0.05）；实验组患者的白细胞和血小板的减少量明显低于对照组，差异显著，有统计学意义（P〈0.05）。结论化疗联合贝伐单抗治疗非小细胞肺癌的治疗效果显著，降低白细胞和血小板的减少量。

ObjectiveThe clinical study of chemotherapy combined with bevacizumab in treatment of non-smal cel lung cancer is to be investigated.Methods 44 cases of patients with non-small cell lung cancer who were treated in our hospital from November 2013 to November 2014 were selected. According to the order of admission,the patients were divided into two groups,namely,experimental group and control group. The chemotherapy combined with bevacizumab is adopted in the experimental group,and the common simple chemotherapy is adopted in the control group. Then the patients’treatment effects of the two groups were observed.ResultsThe total treatment effective rate of the patients in the experimental group was significantly higher than that in control group,with statisticaly significant difference（P〈0.05）; The reducing amount of leucocyte and the blood platelet in the experimental group is significantly lower than that in control group,with statisticaly significant difference（P〈0.05）.Conclusion With remarkable effects and ability to lessen the reducing amount of leucocyte and the blood platelet,the chemotherapy combined with bevacizumab in treatment of non-smal cel lung cancer should be promoted in clinical treatment.